Osteogenesis Imperfecta Management and Genetic Insights

Osteogenesis imperfecta (OI) comprises a spectrum of hereditary connective tissue disorders characterised by bone fragility, low bone mass and recurrent fractures. Predominantly caused by dominant mutations in COL1A1 and COL1A2, OI also arises from defects in at least 18 other genes involved in collagen synthesis, post-translational modification, folding and mineralisation. Clinical management has traditionally centred on immobilisation and intravenous bisphosphonate therapy to reduce bone resorption and improve skeletal strength, but emerging strategies combine antiresorptive agents with bone anabolic approaches and targeted molecular therapies. Advances in genomic sequencing, transcriptomics and functional studies have elucidated novel pathogenic mechanisms—from aberrant intramembrane proteolysis to deep intronic variants affecting pre-mRNA splicing—offering new avenues for personalised medicine. Integration of genetic diagnosis, multidisciplinary care and innovative therapeutics is reshaping global standards for OI management and improving long-term outcomes.

Research from Nature Portfolio

Seminal work has identified mutations in MBTPS2, encoding site-2 metalloprotease, as the cause of an X-linked form of OI. Defective intramembrane proteolysis of transcription factors such as OASIS, ATF6 and SREBP leads to impaired type I collagen secretion, reduced lysine hydroxylation and compromised osteoblast differentiation, illuminating the critical role of regulated proteolysis in bone development. Complementary studies in zebrafish have characterised the organism’s three collagen type I chains, revealing co-regulation, tissue-specific stoichiometry and post-translational modifications during skeletogenesis. These insights validate zebrafish as a tractable model for dissecting collagen biology and for preclinical testing of OI therapies.

Osteogenesis Imperfecta Management and Genetic Insights publication trend

The graph below shows the total number of articles in osteogenesis imperfecta management and genetic insights across all publications each year (not limited to Nature Index journals).

Technical terms

Collagen type I: The primary structural protein of bone extracellular matrix, formed by two α1 and one α2 chains.

Bisphosphonates: Antiresorptive drugs that inhibit osteoclast-mediated bone degradation to increase bone density.

Sclerostin antibody: A monoclonal agent that neutralises sclerostin, enhancing osteoblast activity and bone formation.

Intramembrane proteolysis: Cleavage of membrane-bound proteins by specialised proteases, regulating transcription factor activation.

Endochondral ossification: The process whereby cartilage templates are replaced by bone during skeletal development.

Pre-mRNA splicing: Removal of introns from nascent RNA transcripts to generate mature messenger RNA.

References

1. The IFITM5 mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect. Journal of Clinical Investigation (2024).
2. A progeroid syndrome caused by a deep intronic variant in TAPT1 is revealed by RNA/SI‐NET sequencing. EMBO Molecular Medicine (2023).
3. MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. Nature Communications (2016).
4. Zebrafish Collagen Type I: Molecular and Biochemical Characterization of the Major Structural Protein in Bone and Skin. Scientific Reports (2016).
5. Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research. JBMR Plus (2019).